Clinton Bybee's Net Worth

$2.01 Billion

Who is Clinton Bybee?

Clinton Bybee has an estimated net worth of $2.01 Billion. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., KYTHERA BIOPHARMACEUTICALS INC, PHASERX, INC., Neumora Therapeutics, Inc., Lyell Immunopharma, Inc., ADESTO TECHNOLOGIES Corp, AGIOS PHARMACEUTICALS INC, NeurogesX Inc, VBI VACCINES INC., Receptos, Inc., Gossamer Bio, Inc., Scholar Rock Holding Corp, Pulmatrix, Inc., Karuna Therapeutics, Inc., bluebird bio, Inc., Denali Therapeutics Inc., FATE THERAPEUTICS INC, Sage Therapeutics, Inc., Vir Biotechnology, Inc., Beam Therapeutics Inc., Metacrine, Inc., Bellerophon Therapeutics, Inc., Unity Biotechnology, Inc., Syros Pharmaceuticals, Inc., Codiak BioSciences, Inc., Sienna Biopharmaceuticals, Inc., Juno Therapeutics, Inc., Homology Medicines, Inc., Achaogen Inc, Trubion Pharmaceuticals, Inc, CELEBRATE EXPRESS, INC., 908 Devices Inc., Quanterix Corp, Twist Bioscience Corp, XTERA COMMUNICATIONS, INC., ALNYLAM PHARMACEUTICALS INC, IMPINJ INC, XCYTE THERAPIES INC, and ILLUMINA INC.

SEC CIK

Clinton Bybee's CIK is 0001219043

Past Insider Trading and Trends

2021 was Clinton Bybee's most active year for acquiring shares with 43 total transactions. Clinton Bybee's most active month to acquire stocks was the month of July. 2021 was Clinton Bybee's most active year for disposing of shares, totalling 48 transactions. Clinton Bybee's most active month to dispose stocks was the month of September. 2023 saw Clinton Bybee paying a total of $25,500,000.00 for 18,924,704 shares, this is the most they've acquired in one year. In 2012 Clinton Bybee cashed out on 2,308,783 shares for a total of $919,768.08, their largest year based on trade value.